Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors Journal Article
| Authors: | Kortmansky, J.; Shah, M. A.; Kaubisch, A.; Weyerbacher, A.; Yi, S.; Tong, W.; Sowers, R.; Gonen, M.; O'reilly, E.; Kemeny, N.; Ilson, D.; Saltz, L. B.; Maki, R. G.; Kelsen, D. P.; Schwartz, G. K. |
| Article Title: | Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors |
| Abstract: | Purpose: Preclinical studies indicate that the cyclin-dependent kinase and protein kinase C inhibitor 7-hydroxystaurosporine (UCN-01) potentiates the cytotoxic effects of fluorouracil (FU). We designed a phase I clinical trial of FU in combination with UCN-01. Patients and Methods: FU was administered as a weekly 24-hour infusion. Doses were escalated in successive cohorts according to a modified Fibonacci design. UCN-01 was administered once every 4 weeks, immediately after disconnection from FU, at a dose of 135 mg/m 2 over 72 hours in cycle 1 and 67.5 mg/m 2 over 36 hours in subsequent cycles. FU and UCN-01 pharmacokinetics were obtained on all patients, and thymidylate synthetase (TS) activity was measured in peripheral-blood mononuclear cells by reverse-transcriptase polymerase chain reaction. Results: We escalated the weekly FU dose to 2,600 mg/m 2 in combination with once a month infusions of UCN-01. Dose-limiting toxicity included arrhythmia and syncope. Other toxicities included hyperglycemia, headache, and nausea and vomiting. The mean maximal plasma concentration of UCN-01 was 33.5 μmol/L. There was significant interpatient variability, which correlated with plasma concentrations of alpha-1 acid glycoprotein. FU was rapidly cleared and the dose had no effect on the area under the curve of UCN-01. Changes in TS expression were detectable in peripheral-blood mononuclear cells after administration of UCN-01 but did not correlate with toxicity or activity. We observed no objective response, although seven patients had stable disease, six of whom had received prior fluoropyrimidines. Conclusion: The combination of weekly infusions of FU and monthly UCN-01 can be administered safely and warrants further study in phase II trials. The recommended phase II dose of FU in combination with monthly UCN-01 is 2,600 mg/m 2. © 2005 by American Society of Clinical Oncology. |
| Keywords: | adult; clinical article; controlled study; protein expression; treatment response; aged; clinical trial; constipation; drug tolerability; fatigue; fluorouracil; advanced cancer; area under the curve; cancer combination chemotherapy; diarrhea; dose response; monotherapy; solid tumor; cancer patient; binding affinity; reverse transcription polymerase chain reaction; controlled clinical trial; multiple cycle treatment; sensory neuropathy; anemia; blood toxicity; stomatitis; myalgia; enzyme activity; abdominal pain; drug dose escalation; dyspnea; fever; hyperglycemia; syncope; heart palpitation; hypotension; drug clearance; nausea and vomiting; hyperbilirubinemia; headache; drug blood level; maximum tolerated dose; phase 1 clinical trial; drug half life; heart arrhythmia; thymidylate synthase; cyclin dependent kinase inhibitor; hypoxemia; heart atrium fibrillation; fluoropyrimidine derivative; abdominal cramp; drug binding; peripheral blood mononuclear cell; muscle cramp; protein kinase c inhibitor; pharyngitis; 7 hydroxystaurosporine; orosomucoid |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 23 |
| Issue: | 9 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2005-03-20 |
| Start Page: | 1875 |
| End Page: | 1884 |
| Language: | English |
| DOI: | 10.1200/jco.2005.03.116 |
| PROVIDER: | scopus |
| PUBMED: | 15699481 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 67" - "Export Date: 24 October 2012" - "CODEN: JCOND" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work